Patents by Inventor Martin Gerl

Martin Gerl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7169562
    Abstract: The invention relates to a process for detecting or determining a C-peptide-containing impurity in a sample of recombinantly produced human insulin or a derivative thereof, by a non-radioactive assay, comprising the steps: (a) preparing a sample of recombinantly produced human insulin or a derivative thereof; (b) mixing the samples with dilution buffer; (c) adding a tracer to mixture (b); (d) adding antibody specific for the C-peptide impurity to mixture (c); (e) adding “C-peptide second antibody bead” having at least one label to mixture (d); and (f) detecting or determining the presence of the C-peptide-containing impurity.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: January 30, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Martin Gerl, Cornelia Steinert
  • Patent number: 6365572
    Abstract: Low molecular weight peptide derivatives which are able to act as inhibitors of the interaction between laminin and nidogen (laminin/nidogen interaction), a process for their preparation, pharmaceutical compositions prepared therefrom and their use for preparing pharmaceuticals and for identifying inhibitors of the laminin/nidogen interaction.
    Type: Grant
    Filed: February 29, 2000
    Date of Patent: April 2, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Hans Ulrich Stilz, Martin Gerl, Gary A. Flynn, Magda Stankova, Robert A. Binnie
  • Publication number: 20010007020
    Abstract: The invention relates to monoclonal and polyclonal antibodies, and their parts, which bind specifically to the nidogen-binding domain of laminin, to processes for their preparation and to their use as pharmaceuticals, as diagnostic agents for detecting laminin isoforms and as model substances for developing and evaluating substances which affect the nidogen/laminin interaction. The antibodies according to the invention, or their parts, bind preferentially to the laminin &ggr;1 III 4 domain, in particular in the highly conserved region of the a and c loops, and are able to inhibit the association of laminin and nidogen.
    Type: Application
    Filed: July 15, 1999
    Publication date: July 5, 2001
    Applicant: HOECHST AKTIENGESELLSCHAFT
    Inventor: MARTIN GERL
  • Patent number: 6033863
    Abstract: Monoclonal antibodies for selective immunological determination of high molecular weight, intact laminin forms in body fluids. The present invention relates to monoclonal antibodies for the selective immunological determination of high molecular weight forms of laminin in body fluids, to a process for preparing these antibodies, and to their use for diagnosing diseases. The antibodies according to the invention preferably bind to intact, native laminin, in particular to the structures of the laminin P1 domain of the laminin which are folded in a native manner.
    Type: Grant
    Filed: January 29, 1998
    Date of Patent: March 7, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Martin Gerl, Cornelia Steinert, Manfred Quint, Rupert Timpl
  • Patent number: 5811268
    Abstract: Monoclonal antibodies directed to the laminin P1 domain for selective immunological determination of native, high molecular weight, intact laminins in body fluids; a process for preparing these antibodies; and their use for diagnosing diseases. These antibodies preferably bind to intact, native laminin, in particular to the structures of the laminin P1 domain of laminin which are folded in a native manner.
    Type: Grant
    Filed: August 9, 1995
    Date of Patent: September 22, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Martin Gerl, Cornelia Steinert, Manfred Quint, Rupert Timpl
  • Patent number: 5663291
    Abstract: A process for obtaining insulin having correctly linked cystine bridges from a corresponding proinsulin amino acid chain in the presence of mercaptan, chaotropic auxiliaries and at a pH of 10 to 11 is described, as well as the direct conversion of the proinsulin to insulin with the aid of enzymes and direct isolation of the insulin from the reaction mixture with the aid of hydrophobic adsorber resins.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: September 2, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Rainer Obermeier, Martin Gerl, Jurgen Ludwig, Walter Sabel
  • Patent number: 5473049
    Abstract: A process is described for obtaining proinsulin possessing correctly linked cystine bridges from a corresponding proinsulin amino acid chain in the presence of mercaptan and chaotropic auxiliary agents and at a pH of 10 to 11, as well as its direct isolation from the reaction mixture using hydrophobic adsorber resins.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: December 5, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Rainer Obermeier, Martin Gerl, Jurgen Ludwig, Walter Sabel